Frontline Heroes Office commends Abu Dhabi Global Healthcare Week 2025
Abu Dhabi – The 'Frontline Heroes' Office commended the launch of Abu Dhabi Global Healthcare Week 2025, taking place from 15 to 17 April, as part of the emirate's ongoing efforts to promote healthy lifestyles, disease prevention, and to realize future visions of high-quality, sustainable, and efficient healthcare systems.
The "Frontline Heroes' Office affirmed that this event serves as an inspiring platform to enhance global collaboration and highlight the exceptional efforts of frontline heroes and their vital role in building resilient healthcare systems and strengthening community health security. It also contributes to advancing their preparedness by exploring global best practices in health innovation, prevention, medical education, and workforce development. This aligns with the vision of the wise leadership, which places health at the heart of national priorities, viewing it as a fundamental investment in the present and future of humanity.
The office noted that Abu Dhabi Global Healthcare Week 2025 is not only an exceptional event on the global healthcare calendar, but also a key milestone in shaping the future of health on a global scale and reaffirming the UAE's position as a global hub for innovation and positive impact in the lives of communities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
17-04-2025
- Al Etihad
DoH partners with Gilead Sciences to propel healthcare innovation, cell therapy advancement
17 Apr 2025 18:59 ABU DHABI (ALETIHAD)As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW).As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the the presence of Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said, 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences, commented, 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.'
Zawya
17-04-2025
- Zawya
Cleveland Clinic Abu Dhabi unveils new technologies to support cancer patients
Cleveland Clinic Abu Dhabi has introduced a series of new technologies and initiatives aimed at enhancing cancer patient care, as part of its participation in Abu Dhabi Global Healthcare Week 2025. In statements to the Emirates News Agency (WAM), Dr. Stephen R. Grobmyer, Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi - Fatima bint Mubarak Centre, said that while the hospital is showcasing the latest cancer treatments, the main focus is on supportive care, especially during the most challenging phases of treatment. 'Our goal is not only to provide medical care, but to deliver a holistic, human-centred experience that respects patients' needs and supports them throughout their health journey,' he said. As part of this approach, the hospital launched an innovative programme using the BioButton wearable device, now in use with cancer patients at the Fatima bint Mubarak Centre. The technology enables remote monitoring after patients are discharged, helping detect symptoms and complications early and allowing for timely intervention. This, Grobmyer said, improves patient safety and comfort during recovery. The hospital also introduced solutions to reduce the side effects of chemotherapy, one of the most pressing challenges faced by patients. These include a scientifically validated cooling cap worn during chemotherapy to significantly reduce hair loss—a side effect that often has psychological impacts. In addition, a hand-cooling system is being used with certain treatments to help prevent nerve damage and chemotherapy-induced neuropathy.
Zawya
17-04-2025
- Zawya
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement
This collaboration supports Abu Dhabi's commitment to building a resilient healthcare ecosystem that prioritises preventative, personalised and comprehensive care Abu Dhabi, UAE: As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the emirate In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences. Reflecting Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for communities. This strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare practices. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences commented: 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our l contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.' ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@ About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017. About Kite Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.
